arrow
P

Patrick Lillie

north bristol nhs trust
H指数:45
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial

重组带状疱疹疫苗与mRNA COVID-19或佐剂流感疫苗联合接种的免疫原性和安全性:一项随机对照试验

2026-08-011
PRE
COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research Network

COVID-19相关死亡率:一项来自英国血液恶性肿瘤研究网络的真实世界研究,研究对象为18 883例患有癌前病变和恶性血液肿瘤患者。

2025-11-010
PRE
Development and evaluation of a high-fidelity, multi-disciplinary simulation training course for high-consequence infectious diseases using fluorescence visualization

使用荧光可视化开发和评估高后果传染病的高保真,多学科模拟培训课程

2025-03-010
OAAI
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
2023-09-0120
OAAI
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study-A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

Com-COV2研究中异源COVID疫苗接种计划中免疫反应的持久性-一项纳入mRNA,病毒载体和蛋白质佐剂疫苗的单盲,随机试验

2023-06-017
OAAI
P10 Biomarker Driven Antifungal Stewardship in Acute Leukaemia (BioDriveAFS)-a multicentre randomized controlled trial to assess clinical and cost effectiveness
2022-05-310
OAAI
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

在英国 (Com-COV2),掺入mRNA,病毒载体和蛋白质佐剂疫苗的异源新型冠状病毒肺炎初次疫苗接种的免疫原性,安全性和反应原性: 一项单盲,随机,2期,非劣效性试验

LANCET
IF88.5
2022-01-01169
OAAI
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

ChAdOx1 nCoV-19 (AZD1222) 疫苗对SARS-CoV-2相关变异202012/01 (B.1.1.7) 的疗效: 一项随机对照试验的探索性分析

LANCET
IF88.5
2021-04-01410
OAAI
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
LANCET
IF88.5
2021-03-01841
OAAI